重庆智翔金泰生物制药股份有限公司 关于增加设立募集资金专项账户并签署募集资金 专户存储三方监管协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意重庆智翔金泰生物制药股份有限公 司首次公开发行股票注册的批复》（证监许可〔2023〕725 号），重庆智翔金泰 生物制药股份有限公司（以下简称"公司"）首次公开发行人民币普通股 9,168.00 万股，发行价格为每股 37.88 元，共募集资金 347,283.84 万元，扣除发行费用后 募集资金净额为 329,140.14 万元。上述资金已于 2023 年 6 月 15 日到位，信永中 和会计师事务所（特殊普通合伙）对公司本次公开发行新股的资金到位情况进行 了审验，并于 2023 年 6 月 15 日出具了 XYZH/2023BJAA11B0462 号《验资报告》。 为规范公司募集资金管理和使用，保护投资者权益，公司设立了相关募集资 金专用账户。募集资金到账后，已全部存放于董事会批准开设的募集资金专项账 户内，公司已 ...

| 发行名称 | 2023年首次公开发行股份 | | --- | --- | | 募集资金到账时间 | 2023年6月15日 | 关于归还临时补充流动资金的募集资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 截至 2026 年 3 月 16 日，公司已累计归还临时补充流动资金的闲置募 集资金人民币 50,000 万元。 一、募集资金临时补充流动资金情况 证券代码：688443 证券简称：智翔金泰 公告编号：2026-012 重庆智翔金泰生物制药股份有限公司 重庆智翔金泰生物制药股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开第二届董事会第二次会议、第二届监事会第二次会议，审议通过了《关 于使用部分闲置募集资金临时补充流动资金的议案》，根据公司募集资金投资项 目的资金使用计划及项目的建设进度，同意公司在确保不影响募集资金投资项目 建设进度，不改变募集资金用途，不影响募集资金投资计划正常进行的前提下， 为了提高募集资金使用效率、降低公司财务成本、解决公司运营发展的资金需求， 使用不 ...

Core Viewpoint - The commercial challenges for Zhixiang Jintai (智翔金泰) are just beginning, despite significant revenue growth and reduced losses in 2025 [1][10]. Financial Performance - In 2025, Zhixiang Jintai achieved a revenue of 231 million yuan, a year-on-year increase of nearly 666.65% [2]. - The net loss for the company was 536 million yuan, which represents a 32.74% reduction in losses compared to the previous year [2][9]. - Operating cash flow net outflow significantly narrowed to 261 million yuan in the first three quarters of 2025, down from 423 million yuan in the same period of 2024, primarily due to sales collections and the receipt of upfront payments [7]. Product Development and Sales - The revenue growth was driven by two main factors: the sales volume of the first commercial product, Sailiqi monoclonal antibody (金立希®), and a one-time licensing income from overseas collaboration on GR1803 [3][4]. - Sailiqi monoclonal antibody generated sales revenue of 45.38 million yuan in the first half of 2025, contributing significantly to the total annual revenue of 230 million yuan [15]. - The product was included in the national medical insurance directory in December 2025, which is expected to enhance its market penetration by reducing patient out-of-pocket costs by over 60% [12]. Market Position and Competition - The IL-17A market is competitive, with six approved products in China, including Novartis' first-mover product, which poses a challenge for Zhixiang Jintai to maintain market share despite its lower pricing strategy [16]. - The company has a diversified pipeline that includes products for infectious diseases and oncology, with significant collaborations to alleviate financial pressure and leverage established distribution channels [17][19]. Strategic Approach - Zhixiang Jintai's strategy focuses on a combination of in-house development for autoimmune products and partnerships for infectious disease products, which helps control costs and mitigate risks [20]. - The company has demonstrated its ability to develop drugs and secure partnerships, but it now faces the challenge of proving its commercial viability and sustainability in the market [20]. Future Outlook - The high growth in 2025 is seen as just the beginning, with the real commercial challenges expected to unfold in 2026 [21].

北京市万商天勤律师事务所 关于重庆智翔金泰生物制药股份有限公司 2026 年第一次临时股东会的 法律意见书 致：重庆智翔金泰生物制药股份有限公司 北京市万商天勤律师事务所（以下简称"本所"）接受重庆智翔金泰生物制 药股份有限公司（以下简称"公司"）的委托，指派律师出席了公司召开的2026 年第一次临时股东会。根据《中华人民共和国公司法》、《中华人民共和国证券 法》、《上市公司股东会规则》（下称"《股东会规则》"）等法律、法规和规范性 文件以及《重庆智翔金泰生物制药股份有限公司章程》（下称"《公司章程》"） 的要求，就公司 2026 年第一次临时股东会（下称"本次股东会"）的相关事宜 出具本法律意见书。 公司已向本所律师提供了本所律师认为出具本法律意见书必要的文件资料， 本所律师对该等文件和资料进行了核查、验证，并据此出具法律意见。 1 北京市万商天勤律师事务所 关于重庆智翔金泰生物制药股份有限公司 2026 年第一次临时股东会的 法律意见书 本所律师仅就本次股东会的召集、召开程序、出席会议人员资格、召集人 资格及会议表决程序、表决结果是否符合《公司法》、《股东会规则》以及《公 司章程》发表意见。 本所律师同意 ...

证券代码：688443 证券简称：智翔金泰 公告编号：2026-011 重庆智翔金泰生物制药股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 （二） 股东会召开的地点：重庆市江北区金源路 9 号 重庆君豪大饭店 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 69 | | --- | --- | | 普通股股东人数 | 69 | | 2、出席会议的股东所持有的表决权数量 | 235,897,742 | | 普通股股东所持有表决权数量 | 235,897,742 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 64.4734 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 64.4734 | （四） 表决方式是否符合《公司法》及公司章程的规定，股东会主持情况等。 本次股东会由董事会召集，会议采取现场投票和网络投票相结合的表决方式。 本次股东会的现场会议由董事长刘志刚先生主持，本次股东会的召集和召 ...

Group 1 - The core viewpoint of the article is that Zhixiang Jintai adheres strictly to national tax laws and regulations, confirming that the applicable VAT rate for its sales has consistently been 13% and has not been affected by policy changes [1] Group 2 - The company responded to investor inquiries on an interactive platform, emphasizing its compliance with tax policies [1] - The company reassured investors that its sales operations remain stable and unaffected by any recent changes in tax policy [1]

Group 1 - The core viewpoint of the article highlights the positive impact of the inclusion of the drug "赛立奇单抗" in the national medical insurance directory, which has significantly improved the product's access efficiency [1] - The company, 智翔金泰, is committed to actively promoting the access work to enhance drug availability and aims to benefit more patients [1]

Core Viewpoint - The company has adjusted its fundraising plans, reducing capacity investment, which raises questions about the expected sales of its current and upcoming products [2]. Group 1: Production Capacity - The company has established a production capacity of 24,400 liters for antibody raw materials, which is sufficient to meet the commercial production needs for products like the Celerion monoclonal injection and the Slevem monoclonal injection before 2030 [2]. - The company is optimizing its production schedule and enhancing production processes to ensure that current capacity meets the clinical production needs of other products under development [2]. Group 2: Future Expansion - The second phase of the company's antibody industrialization base project has completed the main building's topping-out and is scheduled to commence production in 2030, which will further expand the company's antibody raw material production capacity [2]. - The adjustments in fundraising and the addition of new sub-projects are based on the company's actual research and operational needs, which will facilitate the smooth implementation of related research and operations and improve the efficiency of fundraising utilization [2].

Financial Performance Summary - In 2025, the company achieved total operating revenue of 230.72 million yuan, representing a growth of 666.65% compared to the previous year [1] - The net profit attributable to the parent company was a loss of 536.22 million yuan, which is a 32.74% reduction in losses year-on-year [1][2] - The net profit attributable to the parent company after deducting non-recurring gains and losses was a loss of 579.22 million yuan, with a 27.99% reduction in losses compared to the previous year [1] Asset and Equity Status - As of the end of the reporting period, the company's total assets amounted to 2.99 billion yuan, a decrease of 4.87% from the same period last year [2] - The equity attributable to the parent company was 1.58 billion yuan, down 25.49% year-on-year [2] Revenue and Profit Analysis - The significant increase in operating revenue is attributed to the expansion of the sales market for the company's first commercialized product, the Saliqi monoclonal antibody injection, which saw steady growth in sales [2] - The revenue from the licensing and commercialization agreement for the GR1803 injection also positively impacted the company's net profit during the reporting period [2] Drug Development Update - The company announced that its GR1802 injection for adult seasonal allergic rhinitis has passed the primary endpoint in Phase III clinical trials and the new drug application has been accepted by the National Medical Products Administration (NMPA) [4][5] - GR1802 is a fully human anti-IL-4Rα monoclonal antibody that specifically binds to the IL-4Rα on cell surfaces, inhibiting Th2-type inflammatory responses [6] Clinical Trials and Future Prospects - The GR1802 injection has multiple indications in clinical trials, including chronic rhinosinusitis with nasal polyps and chronic spontaneous urticaria, with various stages of clinical trials ongoing [6] - As of the announcement date, only two other drugs targeting the same receptor have been approved for marketing in China [7]

Core Viewpoint - The company Zhixiang Jintai-U (688443.SH) reported significant revenue growth for 2025, driven by the expansion of its first commercial product, but it still faces substantial net losses, indicating a distance from profitability [1][2]. Group 1: Financial Performance - In 2025, Zhixiang Jintai achieved total revenue of approximately 231 million yuan, representing a year-on-year increase of 666.65% compared to 2024 [1]. - The company reported a net loss attributable to shareholders of 536 million yuan, which is a reduction of 32.74% year-on-year [1]. - The net loss excluding non-recurring items was 579 million yuan, with a year-on-year decrease of 27.99% [1]. - As of the end of 2025, the total assets of the company were 2.993 billion yuan, a decrease of 4.87% from the previous year [1]. - The equity attributable to shareholders was 1.584 billion yuan, down 25.49% year-on-year [1]. Group 2: Product Development and Market Expansion - The revenue growth was primarily due to the market expansion of the first commercial product, the monoclonal antibody injection, Saliqi (金立希®), which saw steady sales growth [2]. - The company also benefited from significant licensing income related to the GR1803 injection, positively impacting net profit [2]. - Saliqi is the first fully human anti-IL-17A monoclonal antibody approved in China, with approvals for psoriasis and ankylosing spondylitis in August 2024 and January 2025, respectively [2]. - The company announced that the GR1802 injection for adult seasonal allergic rhinitis met its primary endpoint in Phase III clinical trials, and a new drug application has been submitted and accepted [2]. - Multiple indications for GR1802 are in clinical trials, including chronic sinusitis with nasal polyps and chronic spontaneous urticaria [2][3].